Soros Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Soros Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500,001	Closed	-$91.9M	–	311
2021 Q2	$91.9M	Buy	+500,001	New	+$85.8M	1.55%	16
2017 Q4	–	Sell	-4,800	Closed	-$673K	–	298
2017 Q3	$673K	Buy	+4,800	New	+$652K	0.02%	149

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Soros Fund Management's ALXN Position: Q3 2021 in Review

Soros Fund Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 500,001 shares — an estimated $91.9M sold.

Soros Fund Management first reported a position in ALXN in Q3 2017 and held it in 2 quarters. The position peaked at $91.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Soros Fund Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Soros Fund Management sold 500,001 Alexion Pharmaceuticals shares in Q3 2021, an estimated $91.9M.
Soros Fund Management first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 2 quarters.
Soros Fund Management's Alexion Pharmaceuticals position peaked at $91.9M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Soros Fund Management's 13F filing for Q3 2021, filed 12 Nov 2021.